Just - Evotec Biologics' J.POD® wins CPhI Pharma Award 2022 for Manufacturing Technology and Equipment


Hamburg, Germany, 02 November 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. has been selected as a winner of a CPhI Pharma Award 2022.

Just – Evotec Biologics entered the competition in the category “Manufacturing Technology and Equipment” with its flexible cGMP biomanufacturing plant J.POD®. J.POD® represents a paradigm shift in biologics manufacturing. Just – Evotec Biologics’ cutting-edge AI/ML protein design technologies combined with an industry-leading continuous bioprocessing platform can help de-risk and accelerate biotherapeutics development from lead generation through to Biologics License Application (“BLA”) with the U.S. Food and Drug Administration (“FDA”), while offering cost-effective and truly flexible clinical and commercial supply solutions.

The CPhI Award for Manufacturing Technology and Equipment honours innovation in technologies, products, processes, and services for the manufacture of drugs including, equipment, manufacturing processes, facilities, process controls, and continuous manufacturing. Just – Evotec Biologics was presented with the award during an evening ceremony at the leading trade fair CPhI Worldwide in Frankfurt, Germany. Evotec is exhibiting at CPhI Frankfurt at booth # 90J11, Hall 9.0 at Messe Frankfurt until 03 November 2022. 

Evotec will also be showcasing the first-of-its-kind biotherapeutics manufacturing facility, J.POD® Redmond, WA (US), during its Capital Markets Day on 02 November 2022. Both, a live webcast of the event, starting at 11.00 am PDT (2.00 pm EDT, 7.00 pm CET) and a recording, will be available on www.evotec.com.



Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com.




This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.